Abstract: The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.

Abstract: The present invention is directed to telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.

Abstract: A general stochastic method for synthesizing random oligomers on particles is disclosed. A further aspect of the invention relates to the use of identification tags on the particles to facilitate identification of the sequence of the monomers in the oligomer.

Abstract: Inhibition of the enzyme poly (ADP-ribose) polymerase can delay the onset of senescence and inhibitors of the enzyme can be used to treat diseases caused or exacerbated by cellular senescence.

Abstract: Nucleic acids comprising the RNA component of a mammalian telomerase are useful as pharmaceutical, therapeutic, and diagnostic reagents.

Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies of multiple isotypes. Heterologous antibodies are encoded by immunoglobulin heavy chain genes not normally found in the genome of that species of non-human animal. In one aspect of the invention, one or more transgenes containing sequences that permit isotype switching of encoded unrearranged heterologous human immunoglobulin heavy chains are introduced into a non-human animal thereby forming a transgenic animal capable of producing antibodies of various isotypes encoded by human immunoglobulin genes. Such heterologous human antibodies are produced in B-cells which are thereafter immortalized, e.g., by fusing with an immortalizing cell line such as a myeloma or by manipulating such B-cells by other techniques to perpetuate a cell line capable of producing a monoclonal heterologous antibody.

Abstract: A device and method for efficiently synthesizing diverse molecular products on substrates. A parent vessel 200 contains a suspension of substrates. The suspension is pressurized with argon and transferred to a plurality of reaction vessels 201-209 in one or more reaction vessel banks where monomer addition reactions take place. Optionally, the substrates may be tagged with a tag monomer. A vortexing motor 300 vortexes the contents of reaction vessels 201-209 during monomer addition reactions to enhance synthesis. After the desired monomer and/or tag monomer addition reaction, the suspension is pressurized with argon and transferred back to parent vessel 200 for mixing. Thereafter, the suspension may be pressurized with argon and reallocated among reaction vessels 201-209 for further synthesis.

Abstract: Camouflage materials that are highly visible to humans but inconspicuous to dichromatic animals are provided. The camouflage materials emit, or simulate emission, of light at or about the neutral point of a dichromatic animal. One kind of camouflage material contains a coloring agent, which limits photopic light emissions from the material to occur at or about the neutral point. Another kind of camouflage material contains at least two coloring agents, which limit photopic light emissions to at least two bands of wavelengths. The respective proportions and spectral properties of these coloring agents are chosen so that the combination of photopic light emitted by camouflage materials incorporating them simulates the appearance of monochromatic light at or about the neutral point.

Abstract: The present invention relates to a rational, elegant means of producing, loading and using Class I molecules to specifically activate CD8 cells in vitro, and their therapeutic applications in the treatment of a variety of conditions, including cancer, tumors or neoplasias, as well as viral, retroviral, autoimmune, and autoimmune-type diseases. The present invention also relates to vectors, cell lines, recombinant DNA molecules encoding human .beta.2 microglobulin or Class I MHC molecules in soluble and insoluble form, and methods of producing same.

Abstract: Novel bacteria strains and plants are described which produce and secrete chitinase and other proteins as the result of the introduction of foreign DNA linked to a sequence encoding chitinase, an enzyme capable of degrading chitin present in fungi and nematodes. The bacterial strains have utThis invention was made with Government support under Grant No. 1S1-8560311 awarded by the National Science Foundation. The Government has certain rights in this invention.

Abstract: Chimeric G-protein linked receptors are constructed which retain ligand binding specificity yet gain the ability to elevate intracellular free calcium as a result of agonist binding. This easily assayed function is provided by the insertion of or replacement with sequences substantially homologous to the i3 loop of a second G-protein-linked receptor. Such receptors are employed, for example, in methods of screening for compounds capable of acting as agonists or antagonists of G-protein-linked receptors.

Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting mammalian IgE binding factor activity. One of these clones contains an open reading frame consisting of 556 codons. The cDNA is derived from messenger RNA isolated from a rat/mouse T-cell hybridoma line. The cDNA was cloned by incorporation into a pcD plasmid vector. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA to form a polypeptide having IgE potentiating activity after transfection into a mammalian host cell, such as monkey Cos7 cells.

Abstract: Plasmid vectors are provided that carry complementary DNA (cDNA) clones coding for polypeptides exhibiting mammalian multi-lineage growth cell activity. One of these polypeptides is 166 amino acids in length, including a potential leader sequence of about 19 amino acids. The cDNA is derived from messenger RNA isolated from a mouse T-cell line after activation with concanavalin A. The cDNA was cloned by incorporation into a plasmid vector, which was then transformed into E. coli. The plasmid vector also contains DNA segments from the SV40 virus, permitting expression of the cDNA after transfection into a mammalian host cell, such as monkey COS-7 cells.

Abstract: A hybridoma for production of monoclonal antibodies specific for mouse interleukin-2, but which antibodies do not significantly cross-react with human or rat interleukin-2. The hybridoma is a fusion product of a mouse myeloma cell line and from a rat immunized with supernatant from a mouse T cell line.